Health Care: Trump Focuses on Drug Pricing Experiments, ACA and Research Grants | Skadden, Arps, Slate, Meagher & Flom LLP

President Donald Trump issued an administrative order in the first week of his appointment, had a significant impact on the life science and healthcare industry, which indicates the substantial deviation from the previous administration, and in some cases, in some cases. Ta.

First, President Trump January 20, 2025, presidential order Canceled the following execution behavior by former President Joe Biden.

• Presidential Order 14087In accordance with the fact that “reduction of American prescription drug costs”, medical care and Medicade Innovation Center (CMMI) were created. Three drug price setting experiments: Medical value drug wrist model, cells and genetic treatment access models, and accelerated clinical evidence models.
• Presidential Order 14070“We will continue to strengthen American access to affordable high quality health insurance.” This is to expand the health insurance plan of affordable price care (ACA) by providing a longer registration period in most states to the brokers that support ACA and providing additional funds. There is. Registration.
• It was implemented in response to COVID-19 pandemic, and several administrative orders were implemented to prepare for future infections, such as examinations, research, economic rescue, and international cooperation.

On January 20, 2025, President Trump issued a presidential order to notify the administration’s intention. Withdraw from the World Health Organization (Presidential ordinance 14155).

Apart from that, the Trump administration has led the operating department of the Ministry of Health and Welfare (HHS), including the Food Pharmaceutical Bureau (FDA), the Disease Control Prevention Center (CDC), and the National Institute of Health (NIH). All of the external communication and research Grando Review up to February 1, 2025. As a result, a large number of canceled advisory committees and other public meetings could have a potential impact on product sponsors and other industries.

Finally, the Trump administration’s general moratorium regarding public regulations, guidance documents, diversity, fairness, and inclusion (DEI) related (Dei) -lower (Dei) -looked the FDA will be released and released a specific guidance document from that website. The disclosure of other guidance to be planned has been paused. (See us DEI analysis。 )

[View source.]